Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694116 | 1.00 | ATM (0.62) | ATMALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL15224112 | 1.00 | ATM (0.62) | ATMALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| Hydrochloric Acid SCHEMBL7688070 | 0.98 | ATM (0.60) | ATMALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL2682148 | 0.98 | ATM (0.65) | ATMALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| Hydrochloric Acid SCHEMBL856723 | 0.95 | ATM (0.62) | ATMALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL11032090 | 0.87 | LMNA (0.56) | ATMALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL437880 | 0.87 | — | — | |
| Trifluoroacetic Acid SCHEMBL1331170 | 0.87 | ATM (0.48) | ATMALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL15224237 | 0.86 | ATM (0.71) | ATMALDH1A1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL15224234 | 0.86 | ATM (0.71) | ATMALDH1A1SMN1; SMN2L3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2439202-B1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | SALVAT LAB SA (ES) | 2016-04-20 | — | — | EP | disclosed |
| EP-1888546-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2015-07-08 | — | — | EP | disclosed |
| EP-1888546-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2015-07-08 | — | — | EP | disclosed |
| US-8822452-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2014-09-02 | — | — | US | disclosed |
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-8524894-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-7799814-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799814-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799814-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2010-09-21 | — | — | US | disclosed |
| US-20080188531-A1 | Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial, viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries | LABORATOIRES SERONO SA (CH) | 2008-08-07 | — | — | US | disclosed |
| US-20080188531-A1 | Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial, viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries | LABORATOIRES SERONO SA (CH) | 2008-08-07 | — | — | US | disclosed |
| US-20080188531-A1 | Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial, viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries | LABORATOIRES SERONO SA (CH) | 2008-08-07 | — | — | US | disclosed |
| EP-1888546-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006125805-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | ATM 3373/4885ALDH1A1 144/4885SMN1; SMN2 3653/4885 |
| US-20080188531-A1 | Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial, viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries | PDGFRA, PDGFRB, PF4 | ATM 242/4885ALDH1A1 40/4885SMN1; SMN2 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.